CHELMSFORD, Mass., June 20 /PRNewswire/ -- Magellan Biosciences, an emerging leader in clinical-diagnostics markets worldwide, will feature a range of products across the patient-testing continuum -- from community-based testing to hospital and reference labs -- at the Clinical Lab Expo, sponsored by the American Association of Clinical Laboratories (AACC) and American Society for Clinical Laboratory Science (ASCLS), in San Diego, California. All three Magellan companies, ESA Biosciences, Dynex Technologies, and TREK Diagnostic Systems, will feature powerful new products that deliver accurate, reliable results that improve health outcomes, yet are easy to use for even novice lab technicians. The Clinical Lab Expo runs Tuesday, July 17 through Thursday, July 19, 2007, at the San Diego Convention Center.
ESA will feature its CLIA-Waived LeadCare(R) II point-of-care blood-lead analyzer, along with a new esoteric HPLC assay for choline. Visitors to Magellan booth 2647 can also preview LeadLab(TM) -- ESA's blood-lead analyzer for busy clinical labs, currently in development. Dynex will demonstrate its much-heralded DS2(TM) automated two-plate ELISA processing system and its four-plate counterpart, the DSX(R). TREK will feature its Vizion(TM) System, which adds digital-imaging capability to the company's leading antimicrobial- resistance system, Sensititre(R) with SWIN(R) software. Information will also be available on the VersaTREK(R) -- the only diagnostic-laboratory system on the market that can perform four critical tests on one automated platform: blood culture, sterile body fluids, mycobacteria, and mycobacteria susceptibility testing.
According to Magellan President and CEO, Robert J. Rosenthal, PhD, each platform demonstrates Magellan's commitment to understanding customer needs and designing and building world-class products to serve them.
"Since its introduction last fall, ESA's CLIA-waived LeadCare II has begun to change the dynamics of blood-lead testing in this country," said Dr. Rosenthal. "For the first time, we can bring the test directly to those most at risk for lead poisoning, test them, and get their blood-lead levels right there on the spot. We're hearing many success stories -- community health practitioners identifying children with high lead levels and initiating critical follow-up treatment right away; industrial hygiene programs saving time, money, and giving employees peace of mind by doing workplace testing, rather than sending employees to an outside lab. We're now applying many of the technical advances we made with LeadCare II to a clinical-lab analyzer -- LeadLab -- which will be on view at AACC. On the other end of the spectrum, ESA will also be featuring our new esoteric HPLC assay for choline research. Choline is gaining increased attention in the cardiology-research community due to its potential as a biomarker for screening and risk stratification of acute coronary syndrome (ACS)."
Dr. Rosenthal continued, "The DS2 from Dynex Technologies provides unparalleled automation performance to meet the needs of lower-throughput labs performing ELISA/EIA assays, including sample dilution, plate washing, incubation, and accurate and precise optical reading. Designed with full walk-away capability, the DS2 represents a major leap forward in electro- mechanics and software design. Reliable, cost-effective, and easy to use and maintain, the DS2 packs full automation power into the smallest footprint available. The system quickly and easily processes two 96-well microplates and up to 12 different assays simultaneously and features the most user-friendly control system available, chain of custody, and instrument diagnostics. An open system, the DS2 delivers sample-in/results-out automation of virtually any ELISA or EIA microplate assay. Feature-rich and groundbreaking in its process simulation and ease of use, the DS-Matrix(TM) software allows any lab technician to use the DS2 with minimal training, so labs new to automation can rapidly integrate the system with confidence to deliver better and consistently reliable results.
"We're pleased to introduce TREK Diagnostic Systems, the newest member of the Magellan family, a leading provider to microbiology labs. TREK's Vizion System, on display at AACC, takes the guess-work out of reading susceptibility results -- including routine and fastidious isolates, such as Haemophilus, Streptococcus, Mycobacteria, and yeast. It complements TREK's Sensititre with SWIN -- the only system on the market that accommodates testing of the latest antimicrobial therapies in a single, accurate, and cost-effective platform. Vizion provides enhanced lighting options and on-screen display of large, easy-to-read digital images - with quantitative (Minimum Inhibitory Concentration) and qualitative results -- color-coded to eliminate questionable readings and errors (red/resistant, yellow/intermediate, and green/susceptible). A touch-screen capability allows real-time recording of results, and Vizion is the only system that enables users to save and store images for sharing, teaching, and comparison."
About Magellan Biosciences
Magellan serves the worldwide clinical-diagnostics market with rapid point-of-care analyzers and automated systems for hospital-based labs and near-patient testing. Scientists use the company's discovery systems and sensors for cutting-edge research to develop a new understanding of health and illness -- from disease pathology to biomarker identification. Magellan designs all its systems, sensors, and consumables to deliver better, more- reliable results. And better results help drive improved health outcomes: earlier, more-accurate diagnoses; breakthroughs that can lead to novel treatments, new cures -- innovations to enhance life. A privately held company, Magellan serves customers through wholly owned subsidiaries: ESA Biosciences, Dynex Technologies, and TREK Diagnostic Systems. For more information, visit www.magellanbio.com.
About ESA Biosciences
ESA Biosciences, Inc. enables answers to pressing applications challenges by applying its expertise in specialty detection and electrochemistry, combined with components, kits, and reagents, for analytical laboratories, commercial diagnostics laboratories, and the clinical point-of-care setting. ESA is a wholly owned subsidiary of Magellan Biosciences, Inc. For more information, e-mail info@esainc.com, or visit www.esainc.com.
About Dynex Technologies
A Magellan Biosciences company, Dynex Technologies is the innovator in automated and semi-automated technologies for microplate analysis. From walk- away ELISA processing stations like its powerful, two-plate DS2 for low- throughput labs to the renowned four-plate DSX -- Dynex designs each of its products to meet the rigorous demands of scientists in clinical, biomedical, and pharmaceutical-development applications. For more information, visit www.dynextechnologies.com.
About TREK Diagnostic Systems
A Magellan Biosciences company and leader in automated systems and consumables for microbiology-based diagnostic testing, TREK serves the clinical, pharmaceutical, and veterinary markets. TREK's VersaTREK(R) Automated Microbial Detection System and Sensititre(R) Automated Susceptibility and Identification Testing System, are designed to provide cost-effective improvements in workflow efficiencies, ergonomics, and results performance. For more information, visit www.trekds.com.
Magellan BiosciencesCONTACT: Caroline Grossman, +1-781-771-5579, cgrossman@magellanbio.com.com
